Clinical Trials
20 trialsNCT02576431 2026-04-28
NAVIGATE
Bayer
Phase 2 Completed
NCT04280081 2026-04-24
LIBRETTO-321
Eli Lilly and Company
Phase 2 Active not recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT02383927 2024-07-11
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Kura Oncology, Inc.
Phase 2 Completed
NCT00537095 2024-04-19
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
Sanofi
Phase 2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT02702388 2021-11-24
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Eisai Inc.
Phase 2 Completed
NCT00124527 2021-06-16
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Eisai Inc.
Phase 2 Completed
NCT01728623 2020-08-14
A Study of E7080 in Subjects With Advanced Thyroid Cancer
Eisai Inc.
Phase 2 Completed
NCT00784303 2020-04-22
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Eisai Inc.
Phase 2 Completed
NCT02614495 2020-02-13
Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
Hutchmed
Phase 2 Completed
NCT00896454 2018-10-17
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Phase 2 Completed
NCT00098345 2018-05-07
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Sanofi
Phase 2 Completed
NCT02114658 2017-08-03
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Bayer
Phase 2 Completed
NCT01831726 2017-03-20
SIGNATURE
Novartis
Phase 2 Completed
NCT00358956 2017-01-30
A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Sanofi
Phase 2 Completed
NCT00389441 2013-11-25
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Pfizer
Phase 2 Completed
NCT00121628 2013-10-09
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Amgen
Phase 2 Completed
NCT00094055 2012-06-26
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Pfizer
Phase 2 Completed